Global Parenteral Nutrition-Associated Cholestasis Treatment Market By Treatment Type (Medication, Surgery), Drugs (Lipid Injectable Emulsion, Fish Oil Triglyceride, Ursodeoxycholic Acid and Others), Route of Administration (Oral, Injectable), End- Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Others), Geography (North America, South America, Europe, Asia-Pacific, Middle East and Africa) - Industry Trends and Forecast to 2026
Market Analysis: Global Parenteral Nutrition-Associated Cholestasis Treatment Market
Global parenteral nutrition-associated cholestasis treatment market is expected to grow at a substantial CAGR in the forecast period of 2019-2026. Presence of refined healthcare infrastructure and increase in special designation from the regulatory authorities are the key factors that drive the market.
Market Definition: Global Parenteral Nutrition-Associated Cholestasis Treatment Market
Parenteral nutrition-associated cholestasis (PNAC) is a serious liver complication in preterm infants who are administrating prolonged intravenous nutrition. Parenteral nutrition is lifesaving intervention for many preterm infants other neonates with severe illness. The prolonged administration of parenteral nutrition can lead to intrahepatic cholestasis and therefore referred as parenteral nutrition–associated cholestasis. It is condition that impairs the release of digestive fluid called bile from liver cells which results in the accumulation of bile in the liver and hence causes significant damage to the liver.
- Huge financial support to the researchers for developing novel intervention is boosting the market growth
- Increase in demand of disease specific novel treatment can also act as a market driver
- Vulnerable preterm infants receiving parenteral nutrition is driving the growth of the market
- Increase in special designation from the regulatory authorities is drive the market
- Lack of healthcare budget in some middle-income countries is restraining the market growth
- Limited operating revenue opportunities for research and development of targeted therapies by many pharmaceuticals is acting as a challenging factor for the growth of this market
Segmentation: Global Parenteral Nutrition-Associated Cholestasis Treatment Market
- Lipid Injectable Emulsion
- Fish Oil Triglyceride
- Ursodeoxycholic Acid
By Route of Administration
By End Users
- Specialty Clinics
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- North America
- South America
- Rest of South America
- United Kingdom
- Rest of Europe
- South Korea
- Rest of Asia Pacific
- Middle East & Africa
- South Africa
- Rest of Middle East & Africa
Key Developments in the Market:
In December 2018, Fresenius Kabi AG launched Omegaven (fish oil triglycerides), an injectable emulsion for the treatment of parenteral nutrition-associated cholestasis in pediatric patient. This drug has received an Orphan Drug designation and Priority Review from the FDA. The launch of Omegaven fills the critical gaps in the current nutritional management of pediatric patient suffering from parenteral nutrition-associated cholestasis throughout the United States.
Global parenteral nutrition-associated cholestasis treatment market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of global parenteral nutrition-associated cholestasis treatment market for Global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.
Key Market Players:
Few of the major competitors currently working in the global parenteral nutrition-associated cholestasis treatment market are Teva Pharmaceutical Industries Ltd, Zydus Cadila, ALLERGAN, Endo Pharmaceuticals Inc, ANI Pharmaceuticals, Inc, Mylan N.V., Glenmark Pharmaceuticals Ltd, Amneal Pharmaceuticals LLC, Epic Pharma, LLC, Lannett, Fresenius Kabi AG and others
Research Methodology: Global Parenteral Nutrition-Associated Cholestasis Treatment Market
Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analysed and forecasted using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please request an analyst call or can drop down your enquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, other data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Top to Bottom Analysis and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
Demand Side: Doctors, Surgeons, Medical Consultants, Nurses, Hospital Buyers, Group Purchasing Organizations, Associations, Insurers, Medical Payers, Healthcare Authorities, Universities, Technological Writers, Scientists, Promoters, and Investors among others.
Supply Side: Product Managers, Marketing Managers, C-Level Executives, Distributors, Market Intelligence, and Regulatory Affairs Managers among others.
Reasons to Purchase this Report
- Current and future of global parenteral nutrition-associated cholestasis treatment market outlook in the developed and emerging markets
- The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period
- Regions/Countries that are expected to witness the fastest growth rates during the forecast period
- The latest developments, market shares, and strategies that are employed by the major market players